Tom was forty-four years old and had been told by his doctor that his testosterone was “fine.” The number on the lab report was 380 ng/dL. The reference range showed 300 to 1000 ng/dL. Technically in range.
He was also dealing with erectile dysfunction, crushing fatigue, brain fog serious enough to hurt his work performance, loss of muscle mass despite consistent gym attendance, increased body fat especially around the midsection, irritability, and a complete absence of morning erections he’d previously had daily. His doctor said the testosterone was fine and floated the idea he might be depressed. He was not depressed. He was hypogonadal, with additional hormonal dysfunction that a single total testosterone measurement had missed completely.
The male hormone panel — ordered and interpreted comprehensively — tells a story about the entire hypothalamic-pituitary-testicular-tissue axis that single-marker testing can’t begin to approximate.
Total testosterone is one piece of a puzzle that also includes free testosterone (the biologically active fraction), sex hormone-binding globulin (which determines how much testosterone is actually available), LH and FSH (pituitary signals revealing where the dysfunction sits), estradiol (the conversion product of testosterone whose ratio to testosterone matters enormously), DHEA-S, prolactin, cortisol, and thyroid function.
Understanding each component, and how they interact, is what separates accurate hormonal diagnosis from the numerological fiction of “your testosterone is in range, you’re fine.”
Total Testosterone: The Least Useful Starting Point Alone
Total testosterone measures all testosterone in the bloodstream: roughly 60 percent bound to sex hormone-binding globulin (SHBG, tightly bound and not readily available to cells), roughly 38 percent loosely bound to albumin (which can be released relatively easily), and 1 to 3 percent that’s free — unbound, fully available for cellular uptake. Free testosterone plus albumin-bound testosterone together are called bioavailable testosterone.
The reference range problem with total testosterone is significant. The standard range of 300 to 1000 ng/dL (or 270 to 1070 at some labs) was derived from a mix of ages and health statuses, and it’s extraordinarily broad. Mean testosterone in healthy young men (20 to 29) runs roughly 600 to 700 ng/dL.
A 44-year-old man with testosterone of 380 ng/dL is not in the same physiological condition as a healthy 25-year-old with the same number. He’s likely experiencing significant functional hypogonadism.
The reference range also doesn’t account for individual variation in SHBG — the protein that binds testosterone and determines how much is actually available. Two men with identical total testosterone of 380 ng/dL but different SHBG levels have dramatically different amounts of biologically active hormone. The man with SHBG of 20 nmol/L has far more free and bioavailable testosterone than the man with SHBG of 60 nmol/L, despite identical total testosterone numbers.
Interpreting total testosterone without measuring SHBG is, therefore, fundamentally incomplete.
Timing of the draw is critical and frequently ignored. Testosterone follows a circadian rhythm: highest early morning (7 to 9 AM), falling through the day by 30 to 40 percent by afternoon. A testosterone drawn at 3 PM may read significantly lower than one drawn at 8 AM in the same man on the same day.
Standard guidelines recommend testosterone measurements between 7 and 11 AM, fasting, confirmed with a second measurement if the first is low. Single afternoon draws are unreliable and frequently produce both false positives (diagnosing low testosterone in someone with normal but diurnally-reduced levels) and missed diagnoses (explaining away a genuinely low result as just the normal afternoon dip, when it wasn’t actually that profound).
Free Testosterone: The Number That Actually Matters
Free testosterone represents the fraction immediately available for cellular uptake and receptor binding. The biologically active hormone in the most direct sense. In men with hypogonadism symptoms and borderline total testosterone, free testosterone frequently reveals clinically significant deficiency that total testosterone obscures entirely.
Free testosterone can be measured directly by equilibrium dialysis — the gold standard method, plasma placed in a dialysis chamber, the freely diffusing fraction measured separately. Expensive, technically demanding. Most commercial labs use immunoassay methods instead, which correlate poorly with equilibrium dialysis, particularly at low testosterone levels — exactly where the test matters most clinically.
The alternative: calculate free testosterone from total testosterone and SHBG using validated formulas (the Vermeulen equation, or the Morley formula). This calculated free testosterone correlates reasonably well with equilibrium dialysis when accurate total testosterone and SHBG inputs are used.
A man with total testosterone of 380 ng/dL and SHBG of 60 nmol/L has a calculated free testosterone of roughly 7 to 8 ng/dL — below the lower limit of normal for young men (roughly 9 to 11 ng/dL, depending on the lab). The same 380 ng/dL total testosterone with SHBG of 20 nmol/L produces a calculated free testosterone of roughly 13 to 14 ng/dL — within normal range for younger men.
This distinction drives completely different clinical decisions. The first man may benefit from testosterone therapy or SHBG reduction strategies. The second may not need either.
Reference ranges for free testosterone vary by age and are more clinically informative when age-appropriate. The Endocrine Society and the American Urological Association provide age-stratified guidance. A 44-year-old man’s “normal” free testosterone runs lower than a 25-year-old’s, and treating him to 25-year-old reference ranges may be clinically inappropriate.
The clinical question isn’t whether a man falls within the reference range for his age group. It’s whether his symptoms are consistent with functional testosterone deficiency, and whether measured levels correlate with those symptoms.
Sex Hormone-Binding Globulin: The Hidden Regulator
SHBG is the primary determinant of how much of any measured testosterone is actually available to cells. Understanding what drives it up or down is clinically essential — it reveals both why testosterone may run effectively low even with a “normal” total level, and what non-hormonal interventions can improve testosterone bioavailability without pharmacological treatment.
SHBG rises with: estrogens (including phytoestrogens from soy and flaxseed), thyroid hormone excess (hyperthyroidism dramatically increases SHBG), aging (SHBG naturally rises with age, contributing to the decline in free testosterone even when total testosterone holds steady), liver disease (the liver produces SHBG), anticonvulsant medications, and possibly certain dietary patterns including very low fat intake.
SHBG falls with: insulin resistance and hyperinsulinemia (one of the most potent SHBG suppressors — why obese, insulin-resistant men tend to have low SHBG and low total testosterone simultaneously), hypothyroidism, glucocorticoids (cortisol suppresses SHBG), anabolic steroids, growth hormone, and low protein diets.
Notably, low SHBG with low total testosterone can coexist with normal or high free testosterone — tissue exposure to testosterone may actually be adequate even with low total testosterone, if SHBG is also very low. Common in obese, insulin-resistant men, and typically calls for metabolic rather than hormonal intervention.
For men with high SHBG reducing free testosterone bioavailability, several approaches can bring it down: addressing thyroid dysfunction if hyperthyroidism is present; optimizing insulin sensitivity (resistance training, low-glycemic diet, cutting processed carbohydrates); reducing alcohol (alcohol raises SHBG through liver effects); and, controversially, low-dose danazol (an anabolic steroid derivative, used at doses below those causing virilization) in specific clinical contexts under physician supervision. Dietary modification and metabolic optimization come first, before pharmacological SHBG reduction gets considered.
LH and FSH: Locating the Level of Dysfunction
LH stimulates Leydig cells in the testes to produce testosterone. Elevated LH with low testosterone indicates primary hypogonadism — the testes aren’t responding normally to pituitary stimulation. The testes themselves are the site of dysfunction (genetic causes like Klinefelter syndrome, orchitis, chemotherapy or radiation damage, varicocele, or testicular failure from other causes). Here, the pituitary is doing its job. The testes aren’t.
Low or normal LH with low testosterone indicates secondary (central) hypogonadism — the problem sits at the hypothalamus or pituitary level. The pituitary isn’t sending adequate stimulation to the testes.
This pattern shows up in hyperprolactinemia (prolactin suppresses GnRH), Kallmann syndrome (genetic GnRH deficiency), pituitary adenoma (tumor compressing or replacing LH-producing cells), obesity-related functional hypogonadism (adipose tissue aromatase converts testosterone to estradiol, which suppresses the hypothalamic-pituitary axis), and opioid-induced hypogonadism (opioids potently suppress GnRH secretion).
FSH reflects Sertoli cell function and sperm production. In infertility evaluation, FSH is critical: elevated FSH with azoospermia (no sperm) or severe oligospermia suggests primary testicular failure with impaired spermatogenesis. Normal FSH with azoospermia may point to an obstructive cause (blocked vas deferens, congenital bilateral absence of vas deferens) rather than production failure. The distinction guides treatment — primary testicular failure may respond to sperm retrieval techniques; obstructive azoospermia may respond to surgical correction.
The LH/FSH ratio adds more information: an elevated ratio (above 2 to 3) can suggest polycystic-ovary-syndrome-analog patterns, though in men it more commonly indicates hypergonadotropic hypogonadism with differential Leydig cell versus Sertoli cell dysfunction. A thorough hormonal evaluation for hypogonadism has to include LH and FSH — without them, primary can’t be distinguished from secondary hypogonadism, and the treatment implications differ entirely.
Estradiol in Men: Balance, Not Elimination
Estradiol (E2) is not a female-only hormone. Men produce it through aromatase-mediated conversion of testosterone, primarily in adipose tissue, liver, brain, and testes. Men need estradiol — essential for bone density, cardiovascular health, libido (paradoxically), cognitive function, lipid metabolism. The relationship between testosterone and estradiol isn’t adversarial. It’s symbiotic. The goal is balance, not maximum testosterone with minimum estradiol.
Elevated estradiol in men most commonly results from excess aromatase activity, strongly associated with excess adipose tissue (adipocytes are rich in aromatase). The testosterone-to-estradiol ratio — not the absolute estradiol number — is the clinically relevant metric. A commonly used functional threshold: testosterone-to-estradiol ratio above 10 (testosterone in ng/dL, estradiol in pg/mL). Below that ratio, estrogen dominance symptoms (gynecomastia, sexual dysfunction, mood changes, water retention) may show up.
Testosterone of 400 ng/dL with estradiol of 50 pg/mL gives a ratio of 8 — below threshold. The same 400 ng/dL with estradiol of 25 pg/mL gives a ratio of 16 — adequate balance.
Managing elevated estradiol through aromatase inhibition — anastrozole or letrozole, drugs developed for breast cancer treatment — is increasingly used in testosterone replacement therapy protocols to prevent estradiol elevation from aromatization of administered testosterone. Often appropriate during TRT. But aromatase inhibitors shouldn’t be used to aggressively suppress estradiol below normal ranges.
Excessively low estradiol in men causes joint pain (estradiol is essential for cartilage maintenance), bone loss, decreased libido (counterintuitive to anyone assuming all estradiol is bad), and cardiovascular risk. The therapeutic target is estradiol in the 20 to 30 pg/mL range for most men on TRT.
Natural aromatase inhibition through lifestyle is the first-line approach: weight loss reduces adipose aromatase activity, which is why significant weight loss frequently improves testosterone levels and the testosterone-to-estradiol ratio with zero hormonal treatment. Zinc competitively inhibits aromatase in a dose-dependent manner — zinc deficiency permits more aromatization, zinc sufficiency at physiological levels reduces it. Resveratrol and grape seed extract have some evidence as natural aromatase activity modulators, though modest compared to pharmaceutical aromatase inhibitors.
DHEA-S and the Adrenal Androgen Contribution
DHEA (dehydroepiandrosterone) and its sulfated form DHEA-S are produced primarily by the adrenal cortex and represent the largest reservoir of androgen precursors in the body. DHEA-S can be converted peripherally to testosterone and estradiol in tissues expressing the relevant enzymes, providing a significant chunk of total androgen and estrogen activity in both men and women. DHEA-S is the most abundant circulating steroid hormone, and measuring it provides important information about adrenal androgen production separate from testicular testosterone production.
DHEA-S declines dramatically with age — levels in men in their 70s run roughly 20 percent of peak young adult values — contributing to the androgen decline associated with aging. In a male hormone panel, low DHEA-S for age suggests either adrenal insufficiency (if severe), accelerated aging-related decline, or HPA axis suppression from chronic stress, corticosteroid use, or poor sleep.
Very elevated DHEA-S raises concern for adrenal pathology including adrenal carcinoma, which should get evaluated with imaging and additional testing.
DHEA supplementation (25 to 50 mg daily) is used in functional medicine to support adrenal androgen levels, improve fatigue and wellbeing, and partially compensate for age-related DHEA decline. Clinical evidence for DHEA supplementation in men is mixed — the literature confirms benefit for quality of life and body composition in elderly men with low DHEA-S, but the effects are modest and don’t substitute for addressing the underlying drivers of DHEA decline.
DHEA can convert to testosterone but also to estradiol, so baseline estradiol testing and monitoring is appropriate before and during supplementation.
Prolactin: The Testosterone Saboteur
Causes of elevated prolactin include pituitary prolactinoma (the most common pituitary tumor, typically a small microadenoma responding well to dopamine agonist treatment), medications (antipsychotics, metoclopramide, some antidepressants all raise prolactin), hypothyroidism (TRH stimulates both TSH and prolactin secretion — hypothyroidism can cause mild prolactin elevation), nipple stimulation, stress, and macroprolactinemia (prolactin bound to immunoglobulins, giving falsely elevated immunoassay results with no biological activity).
The clinical pattern of secondary hypogonadism with low LH/FSH should always include a prolactin measurement. A man with low testosterone, low LH (appropriate to the low testosterone in secondary hypogonadism), and elevated prolactin has a specific diagnosis — hyperprolactinemia-induced hypogonadism — with a specific treatment (dopamine agonist: cabergoline or bromocriptine) that normalizes prolactin, restores LH and FSH, and typically normalizes testosterone within weeks to months.
A profoundly different situation from primary hypogonadism requiring testosterone replacement. Missing the prolactin measurement means treating the wrong level of the system entirely.
Testosterone Replacement Therapy: When, How, and What to Monitor
Testosterone replacement therapy (TRT) is one of the most prescribed and most debated hormonal treatments in men’s health medicine. Used appropriately — in men with clearly documented symptomatic hypogonadism, after reversible causes are addressed, with proper monitoring — it’s safe and highly effective. Used indiscriminately in men without genuine deficiency or without monitoring, it carries real risks and produces minimal benefit.
Reversible causes of low testosterone should be addressed before starting TRT whenever possible. These include obesity (10 percent or more weight loss can significantly raise testosterone), obstructive sleep apnea (hypoxia and disrupted sleep suppress testosterone — treating OSA can normalize it in affected men), chronic stress and HPA axis dysregulation (persistently elevated cortisol suppresses LH and testosterone), alcohol overuse, zinc deficiency, hypothyroidism. Starting TRT without addressing these produces suboptimal results and can mask the reversible cause entirely.
Laboratory monitoring during TRT requires more than repeating the testosterone level.
Hematocrit (TRT stimulates red blood cell production, and hematocrit above 54 percent increases blood viscosity and thrombotic risk), PSA (for men over 40, though the evidence that TRT significantly worsens prostate cancer risk is less compelling than historically assumed), estradiol (to catch excess aromatization), LH/FSH (which will be suppressed with exogenous testosterone — confirming expected suppression and ruling out abnormal patterns), and testicular size (exogenous testosterone suppresses LH, reducing the intratesticular testosterone required for spermatogenesis — why TRT impairs fertility in men who want to preserve it, and why HCG co-administration gets used to maintain intratesticular testosterone) are all monitored parameters.
Common Questions About Total Testosterone Least
What is the ideal total testosterone level for men?
No single “ideal” number applies universally, but most men feel and function best with total testosterone in the 500 to 900 ng/dL range, free testosterone in the upper half of the reference range for their age. Men below 400 ng/dL with symptoms — particularly free testosterone in the lower quartile — are likely experiencing functional hypogonadism.
Men above 400 ng/dL with prominent symptoms warrant a full panel: free testosterone, SHBG, estradiol, LH, FSH, prolactin — to identify what’s driving symptoms if total testosterone looks adequate on paper. Individual optimization targets should account for symptom burden, metabolic status, and overall hormonal balance rather than chasing a single number.
Does testosterone replacement therapy affect fertility?
Yes, significantly. Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamus and pituitary. Suppressed LH reduces intratesticular testosterone production (needed at concentrations 50 to 100 times higher than systemic levels for spermatogenesis). The result is typically a dramatic drop in sperm count, often to azoospermia, within months of starting TRT. Reversible in most men after discontinuation, but recovery can take six months to two years and isn’t guaranteed.
Men who want to preserve or achieve fertility shouldn’t use TRT without discussing fertility preservation (sperm banking) and alternative hypogonadism treatment options (clomiphene citrate, which stimulates endogenous LH without suppressing the axis, or HCG co-therapy) with their physician.
What natural approaches can optimize testosterone?
Several lifestyle factors have documented effects on testosterone: weight management (visceral fat reduction cuts aromatase activity and improves LH sensitivity); resistance training (multiple studies confirm progressive resistance training raises testosterone, particularly in hypogonadal and older men); adequate sleep (testosterone is produced primarily during sleep; even one week of five-hour nightly sleep reduces testosterone by 10 to 15 percent in young men); zinc and vitamin D sufficiency (both required for testosterone synthesis and receptor function); stress management (chronic cortisol elevation suppresses the HPT axis); and limiting alcohol and environmental xenoestrogen exposure.
These aren’t trivial interventions — a hypogonadal obese man who loses 20 percent of his body weight through diet and exercise may restore testosterone to normal with zero pharmacological treatment.
How is male hormone testing different from what is checked during a standard physical?
Standard annual physicals typically include a complete blood count, comprehensive metabolic panel, lipid panel, and possibly a PSA for men over 50, or 40 with risk factors. Testosterone isn’t part of a standard physical unless the physician orders it based on symptoms. When it is ordered, many physicians order total testosterone only — missing the free testosterone, SHBG, estradiol, LH, FSH, and prolactin that provide the complete hormonal picture.
A comprehensive male hormone panel ordered by a functional medicine physician, urologist, or endocrinologist with interest in hormonal optimization includes all of these markers plus thyroid function (which affects SHBG and overall metabolic function) and often DHEA-S and cortisol. The gap in diagnostic yield between a single total testosterone measurement and a comprehensive panel is substantial enough that the single-marker approach should be treated as a screening test, not a comprehensive evaluation.
Can testosterone panels detect the cause of erectile dysfunction?
Hormonal factors account for roughly 20 percent of erectile dysfunction (ED) in men — low testosterone, elevated prolactin, elevated estradiol, thyroid dysfunction. The other 80 percent is primarily vascular (impaired penile blood flow from cardiovascular disease, diabetes, or medications), neurogenic (nerve damage from diabetes, pelvic surgery, or neurological disease), or psychogenic.
A comprehensive hormone panel is appropriate as part of the ED evaluation, particularly given that hormonal causes are treatable — but a normal hormone panel in an ED patient doesn’t end the investigation. Vascular evaluation (penile Doppler ultrasound), glycemic testing (HbA1c), cardiovascular risk assessment, and medication review (many antihypertensives, antidepressants, and finasteride are associated with ED) complete the picture.
ED in men under 40 is a cardiovascular risk marker — it predicts coronary artery disease by five to ten years in multiple prospective studies, which makes its evaluation important well beyond the sexual function dimension.
The Cortisol-Testosterone Relationship
Both testosterone and cortisol are synthesized from cholesterol through the same basic steroidogenic pathway. The cellular machinery producing adrenal steroids has limited capacity, and under sustained stress, demand for cortisol production effectively crowds out steroid precursor availability for testosterone synthesis. Functional medicine circles call this “pregnenolone steal” — the common precursor pregnenolone diverted toward cortisol production at the expense of DHEA and testosterone.
Whether this mechanism is quantitatively significant in most clinical contexts is debated, but the overall principle — that HPA axis hyperactivation suppresses the HPT axis — is well established across multiple levels of evidence.
At the hypothalamic level, CRH (corticotropin-releasing hormone), the stress signal that initiates cortisol production, also suppresses GnRH secretion. Chronic stress that continuously activates the HPA axis therefore continuously suppresses the HPT axis. At the pituitary level, ACTH (adrenocorticotropic hormone) and LH share regulatory circuitry, and cortisol feedback suppression of ACTH extends to affect LH pulsatility. At the testicular level, cortisol directly inhibits Leydig cell testosterone production through glucocorticoid receptors on the cells.
The practical implication: chronic psychological stress, sleep deprivation, excessive training without adequate recovery (overtrained athletes classically show low testosterone and high cortisol), and any condition driving persistent HPA axis activation will suppress testosterone. A man with testosterone of 350 ng/dL who’s also under severe chronic occupational stress, sleeping six hours a night, and training intensely may restore testosterone to 550 ng/dL simply by managing stress and sleep — no hormonal treatment whatsoever.
Measuring a four-point salivary cortisol or a morning serum cortisol alongside the testosterone panel identifies this driver when it’s present.
The reverse relationship matters too: testosterone has anti-glucocorticoid effects, competing with cortisol for receptor binding and attenuating some of cortisol’s catabolic effects on muscle tissue. Men who are genuinely hypogonadal therefore tend to have worse responses to stress and greater catabolic effects from cortisol exposure — a mechanistic explanation for the psychological fragility and stress intolerance many hypogonadal men report.
The Insulin-Testosterone Axis
Insulin resistance is one of the most powerful suppressors of testosterone in men and is simultaneously caused and worsened by low testosterone — a bidirectional vicious cycle that drives metabolic syndrome in men. Understanding this relationship changes the approach to both conditions.
Testosterone improves insulin sensitivity through several mechanisms: it increases glucose transporter expression in muscle cells, promotes muscle protein synthesis (more muscle mass means more insulin-responsive tissue), reduces visceral fat accumulation, and has direct effects on adipocyte insulin signaling. Conversely, low testosterone promotes visceral fat accumulation (metabolically active and pro-inflammatory), reduces lean muscle mass, and impairs glucose utilization — all of which worsen insulin resistance.
Insulin resistance suppresses testosterone through its effect on SHBG. Hyperinsulinemia reduces hepatic SHBG production (the liver produces less SHBG under high insulin exposure), which reduces total testosterone while potentially maintaining free testosterone (SHBG-bound testosterone is the fraction that falls). But the same insulin resistance also reduces LH sensitivity at the testicular level, reducing total testosterone production on its own.
The net result is the pattern seen in obese, metabolically unhealthy men: low total testosterone, low SHBG, variably low free testosterone, elevated estradiol (from adipose aromatase), suppressed LH — a hormonal profile that’s both a consequence and a driver of metabolic disease.
Fasting insulin (and the derived HOMA-IR score) should be part of any comprehensive male hormone evaluation in men who are overweight or carrying abdominal fat, because managing insulin resistance — through diet, exercise, and if needed medications like metformin — will improve the hormonal profile more durably than testosterone replacement in this population.
A man with classic metabolic syndrome who loses 15 percent of his body weight and reverses insulin resistance may restore his testosterone from 350 to 550 ng/dL with no hormonal intervention at all, simply by addressing the metabolic driver.
Interpreting the Complete Male Hormone Panel: A Practical Framework
Integrating all the components of the male hormone panel into a clinically coherent picture takes a systematic approach. The following framework applies the mechanistic understanding to real clinical situations.
When total testosterone is low and LH is elevated — this is primary hypogonadism. The testes are failing to respond to adequate pituitary stimulation. Causes include Klinefelter syndrome (karyotype testing appropriate), prior cryptorchidism, orchitis history, varicocele, or idiopathic primary testicular failure. Treatment typically requires testosterone replacement. Fertility is usually severely impaired; sperm retrieval techniques with IVF/ICSI may be the only reproductive option.
When total testosterone is low and LH is low or inappropriately normal — this is secondary (central) hypogonadism. The problem sits above the testicular level. Check prolactin (prolactinoma), thyroid function (hypothyroidism can cause secondary hypogonadism), and consider MRI pituitary for macroprolactinoma or other pituitary pathology. Functional causes include obesity, sleep apnea, opioid use, and chronic stress — addressing these may restore the axis without medication.
Clomiphene citrate (which blocks estrogen negative feedback at the hypothalamus, increasing GnRH and LH/FSH) is effective for secondary hypogonadism in men who want to preserve fertility or prefer stimulating endogenous production.
When total testosterone is borderline or normal but free testosterone is low — this is SHBG-mediated functional hypogonadism. Check what’s driving SHBG up (hyperthyroidism, aging, low insulin resistance, certain medications) and address the driver. The relationship between symptoms and free testosterone, rather than total testosterone, guides treatment decisions here.
When testosterone is low with all of the above normal — consider confounding factors: was the sample drawn in the morning? Was biotin use stopped? Was the patient acutely ill? Zinc deficiency, significant sleep deprivation? Extreme caloric restriction? Any of these can produce low testosterone without structural hypogonadism, and addressing the reversible factor is the appropriate first move.
Tom’s complete panel, ordered by his functional medicine physician, showed: total testosterone 380 ng/dL; SHBG 58 nmol/L (high); free testosterone 6.4 ng/dL (below normal); estradiol 18 pg/mL (low-normal, ratio adequate); LH 4.2 mIU/mL (normal, meaning secondary rather than primary hypogonadism etiology); FSH 3.8 mIU/mL (normal); prolactin 8 ng/mL (normal); DHEA-S 145 µg/dL (low for his age); thyroid: TSH 3.8, Free T4 0.85 (low-normal), Free T3 2.2 (low) — a subclinical hypothyroidism pattern.
Elevated SHBG driven in part by subclinical hypothyroidism (hypothyroidism raises SHBG). Low free testosterone driven by that elevated SHBG. Low DHEA-S driven by chronic stress — his cortisol panel showed a flat, blunted diurnal curve.
His treatment addressed each identified driver: thyroid optimization (low-dose T3/T4 combination), stress management and sleep optimization (trimmed a 60-hour work week, implemented sleep protocols), and targeted supplementation (zinc 30 mg, vitamin D 5000 IU, DHEA 25 mg with monitoring).
At eight months, SHBG had fallen from 58 to 38 nmol/L, free testosterone had risen from 6.4 to 11.2 ng/dL, DHEA-S had risen to 240 µg/dL, and the thyroid optimization had brought FT3 into the mid-normal range. The symptoms — fatigue, brain fog, erectile dysfunction, mood — resolved to a point he described as “better than I felt in my thirties.” No testosterone prescription required.
The comprehensive panel had found the actual problem. And the actual problem had a solution that wasn’t testosterone replacement.
Environmental Factors and Male Hormone Disruption
The secular decline in male testosterone levels — multiple large studies showing contemporary men running 15 to 25 percent lower testosterone than men of the same age in the 1980s and 1990s, sperm counts declining roughly 1 percent per year over the past fifty years — implicates environmental factors separate from any individual man’s hormonal panel but directly relevant to understanding why hormonal dysfunction is so prevalent today.
Endocrine-disrupting chemicals (EDCs) — compounds interfering with hormone synthesis, binding, or receptor activation — sit in the modern environment at unprecedented levels.
Bisphenol A (BPA) and its replacements (BPS, BPF) in plastics and thermal paper receipts; phthalates in food packaging, personal care products, medical devices; PFAS (per- and polyfluoroalkyl substances) in non-stick cookware, water-repellent clothing, food packaging; pesticide residues on food — all have documented endocrine-disrupting effects, including reduced testosterone production, impaired sperm function, and interference with sex hormone receptor signaling.
Practical reduction of EDC exposure — filtered water (removes PFAS), glass and stainless steel food containers (reduces BPA/phthalate leaching), organic produce for the highest-pesticide items (the dirty dozen list), fragrance-free personal care products (phthalates are common solvents in fragrance formulations) — cuts ongoing estrogenic and anti-androgenic exposure. Neither trivial nor sufficient on their own for severe hypogonadism, but meaningful background noise reduction for the hormonal system, underappreciated in clinical discussions that focus exclusively on pharmaceuticals.
Light exposure affects testosterone in a mechanistically interesting way. Testicular light exposure through skin — yes, this is real — was documented in a 1939 study (Myerson and Neustadt), and more recently in pilot work on red light therapy applied to testes and chest that produced testosterone increases in small trials.
The mechanism appears to involve photoreceptors in testicular Leydig cells (P450scc and other steroidogenic enzymes show light sensitivity) and possibly vitamin D synthesis and circadian rhythm effects on the HPT axis. Daily outdoor light exposure, both for vitamin D synthesis and circadian entrainment, is a simple optimization with plausible hormonal benefits beyond its general health effects.
The Practical Framework: Applying Total Testosterone Least Useful In Real Life
References